Immunotherapy shows promise against rare sarcomas
NCT ID NCT04458922
First seen Nov 01, 2025 · Last updated Jun 13, 2026 · Updated 28 times
Summary
This study tested a drug called atezolizumab in 27 people with rare cancers of the bone (chondrosarcoma) or soft tissue (clear cell sarcoma) that could not be removed by surgery or had spread. The drug helps the body's immune system attack cancer cells. The main goal was to see if tumors shrank or stopped growing.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CENTRAL CHONDROSARCOMA, GRADE 2 are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Dana-Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
Emory University Hospital Midtown
Atlanta, Georgia, 30308, United States
-
Emory University Hospital/Winship Cancer Institute
Atlanta, Georgia, 30322, United States
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
-
NCI - Center for Cancer Research
Bethesda, Maryland, 20892, United States
-
National Cancer Institute Developmental Therapeutics Clinic
Bethesda, Maryland, 20892, United States
-
National Institutes of Health Clinical Center
Bethesda, Maryland, 20892, United States
-
Ohio State University Comprehensive Cancer Center
Columbus, Ohio, 43210, United States
-
Siteman Cancer Center-South County
St Louis, Missouri, 63129, United States
-
UF Health Cancer Institute - Gainesville
Gainesville, Florida, 32610, United States
-
USC / Norris Comprehensive Cancer Center
Los Angeles, California, 90033, United States
-
University Health Network-Princess Margaret Hospital
Toronto, Ontario, M5G 2M9, Canada
-
University of Pittsburgh Cancer Institute (UPCI)
Pittsburgh, Pennsylvania, 15232, United States
-
Vanderbilt University/Ingram Cancer Center
Nashville, Tennessee, 37232, United States
-
Washington University School of Medicine
St Louis, Missouri, 63110, United States
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.